# INFORMATION DISCLOSURE CITATION

Atty. Docket No.

Divisional of Serial No.

1579-880 Applicant 09/775,805

(Use several sheets if necessary)

HAYNES tal

Group

		Janu	ary 9, 2004			
U.S. PATENT DOCUMENTS    FILING DATE   NAME   CLASS SUBCLASS IF APPROPRIATE						
						FILING DATE
INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	IF APPROPRIATE
		FOR	EIGN PATENT DOCUMENTS			TDANIOLATION
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	(
				1	00002100	1.20 1.0
	OTHER DOCL	JMENTS (in	cluding Author, Title, Date, Pertinen	t pages, et	tc.)	
	Sheppard et al, "The cha AIDS 7:1159-1166 (199	racterization 3)	of non-progressors: long-term HIV-1 infec	ction will sta	ble CD4+ T-	cell levels",
	Phair, John P., Keynote Retroviruses 10(8):883 8	Address: "Va 885 (1994)	•			
	Engl. J. Med. 332(4):209	9- 216 (1995)				
	Type 1 Infection", N. En	igl. J. Med. 3	32(4):201-208 (1995)			•
	_HIV", Nature 3970:463-	<u>467 (1994)</u>				
	<u>  122:573-579 (1995)</u>					
	Clinical Course?", Virol	ogy 204:223-	233 (1994)			
	Human Immunodeficien	cy Virus Typ	e 1 Infection", Journal of Virology 68(9):6	5103-6110 (1	.994)	•
	Haynes et al, "Toward and 328 (1996)	n Understand	ing of the Correlates of Protective Immuni	ty to HIV In	fection", Sci	
	260:1279-1286 (1993)					
	Nowak et al, "Antigenic	oscillations a	and shifting Immunodominance in HIV-1 I	nfections", N	Nature 375:60	06-611 (1995)
	Walker et al, "CD8+ Lyr 234:1563-1566 (1986)	nphocytes Ca	an Control HIV Infection in Vitro by Supp	ressing Viru	s Replication	", Science
	CD8+ T Cells", Science	270:1811-18	15 (1995)			•
	Science 272:872-877 (19	996)				upled Receptor",
	Wei et al, "Viral dynamic	cs in human i	mmunodeficiency virus type 1 infection",	373:117-122	2 (1995)	
	Palker et al, "Polyvalent Cell Sites and B Cell Ner	Human Immi utralization E	unodeficiency Virus Synthetic Immunoger pitopes", The Journal of Immunology 142	Comprised: 3612-3619	of Envelope (1989)	gp120 T Helper
	Berzofsky, Jay A., "Deve 2418 (1991)	elopment of a	rtificial vaccines against HIV using define	d epitopes",	The FASEB	
	Haynes et al, "HIV Type Peptides as a Polyvalent	1 V3 Region Immunogen"	Primer-Induced Antibody Suppression Is, AIDS Research and Human Retroviruses	Overcome b	y Administra 21 (1995)	ation of C4-V3
			1		,	
Examiner			Date Considered			

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

## **INFORMATION DISCLOSURE CITATION**

Divisi nal of Serial No.

1579-880 Applicant

Atty. Docket No.

09/775,805

(Use several sheets if necessary)

**HAYNES** Filing Date

Gr up

		Janu	lary 9, 2004	· · · · · · · · · · · · · · · · · · ·							
*EXAMINER			U.S. PATENT DOCUMENTS								
INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE					
						11 711 1101 111/112					
		FOF	REIGN PATENT DOCUMENTS								
						TRANSLATION					
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES NO					
	OTHER DOCL	JMENTS (ir	cluding Author, Title, Date, Pertinent	pages, et	tc.)						
	of Arizona: A Model for	"HLA Class	I Variation Controlled for Genetic Admixtudioral III	ire in the G	ila River Ind	ian Community					
-	Hardy G H "Mendelia	n Proportion	ndians", Human Immunology 33:39-46 (199 s in a Mixed Population", Science, N.S. XX	2) VIII (706).	10.50 (1000)						
	Schneider et al. "Enhance	ed immunos	enicity for CD8+ T cell induction and comp	viii,(700):	19-30 (1908)	of malaria DNA					
	vaccination by boosting	with modifie	d vaccinia virus Ankara". Nature Medicine	4:397-402	(1998)						
	Ferrari et al, "Clade B-ba	ased HIV-1 ·	vaccines elicit cross-clade cytotoxic T lympl	ocyte reac	tivities in uni	nfected					
	volunteers", Proc. Natl	Acad. Sci. U	SA 94:1396-1401 (1997)								
	Annu Rev Immunol 13	oward A Va	ccine For AIDS: The Emergence of Immur	obiology-E	lased Vaccin	e Development",					
		Rev. Immunol. 12:923-989 (1994) ia et al, "Auxotrophic vaccines for tuberculosis", Nature Medicine 2(3):334-337 (1996)									
	Beddows et al, "Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1, role										
	of V3-specific antibodies", Journal of General Virology 79:77-82 (1998)										
	Sullivan et al, "Replicative Function and Neutralization Sensitivity of Envelope Glycoproteins from Primary and T-Cell										
	Line-Passaged Human In	mmunodefic	ency Virus Type 1 Isolates", Journal of Viro	ology 69(7)	:4413-4422 (	(1995)					
	<del>                                     </del>										
		<del></del>									
					<del></del>						
				· · · · ·		<del></del>					
				· · · · · · · · · · · · · · · · · · ·							
	<del> </del>										
	<del></del>										
						<del></del>					
	· <del> </del>	. <u> </u>									
					<del></del>						
*Examiner			Date Considered								
			Date Considered								

Sheet 3' of '7

INFORM	ATION DISCLOSU	IRE ATTY. DOCKET	NO.	DIVISIONAL OF	SERIAL NO.		
	CITATION	1579-880		09/775,805			
		APPLICANT -					
		HAYNES e	t al				
(Use se	everal sheets if necessary)	FILING DATE		GROUP			
		January 9,	2004				
		U.S. PAT	ENT DOCUMENTS				
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING IF APPRO	
	5,516,632	5/1996	Palker et al				
		<u> </u>					
		<u> </u>		<u> </u>			
_		<del>                                     </del>					
		<u> </u>				ļ	
	<del></del>						
		EODEICN	DATENT DOCUMEN	ITC I	<u> </u>	L	
		POREIGIN	PATENT DOCUMEN	113		ABST	RACT
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	WO 01/56355	8/2001	PCT				
						<del></del>	
<del></del>	OTHER DOCUM	<b>ENTS</b> (includin	g Author, Title, Date	e, Pertinent pa	iges, etc.	)_	
	Rowland-Jones et al,  Med. 1(1):59-64 (199	HIV-Specific Cytoto	oxic T-Cells in HIV-Expos	ed but Uninfected	Gambian V	Nomen,	Nat.
	Wed. 1(1).53-64 (133	o) (Abstract)					
						<u>_</u>	
				<del></del>			
				-	<del></del>		
xaminer			Date Considered				
	reference considered, whether	or not citation is in conforma	nce with MPEP 609; Draw line throu				
opy of this form wi	ith next communication to applic	ation.	TICE WILL WIFEF 609; Draw line throu	ign citation it not in confo	mance and not	considered.	Include
					Form PTO-FB-A	1820 (Also I	PTO-144

\*Examiner

# INFORMATION DISCLOSURE CITATION

Atty. Dock t No.

Divisional of Serial No.

1	57	'9-	8	8(	)
A	opl	cai	nt		_

09/775,805

(Use several sheets if necessary)

HAYNES tal

Group

		Januar	y 9, 2004	· · ·			
		U.S	S. PATENT DOCUMENTS		<del></del>		
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING IF APPR	DATE OPRIAT
				<del></del>			
		FOREIG	GN PATENT DOCUMENTS				
		· OILLI	ATENT DOCUMENTS			TRANS	LATION
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	WO 03/039470	5/2003	PCT				
	WO 01/56355	8/2001	PCT				
	<del> </del>						
							<u> </u>
							<u> </u>
	OTHER DOCL	JMENTS (inclu	ding Author, Title, Date, Pertiner	nt pages, et	(c.)		<u> </u>
	Lee et al, "Circulating H	IV-1-Infectd Ce	ll Burden From Seroconversion to AII	S. Importan	ce of Postser	oconvers	ion
	Viral Load on Disease C	Course", Journal o	of Acquired Immune Deficiency Syndi	romes 7:381-	388 (1994)		
	1(1):59-64 (1995)	IV-specific cytor	toxic T-cells in HIV-exposed but unint	fected Gambi	an women",	Nature M	1edicino
	Wain-Hobson et al, "Sin	non in the Evolu	tionary biology of viruses, Stephen S.	Morse (ed), F	Raven Press,	VY, pgs	185-20
	(1994) – Abstract						
	Robertson et al. "Recom	hination in AIDS	ns and CD4 lymphocytes in HIV-1 inf S Viruses", Journal of Molecular Evolu	fection", Natu	re 373:123-1	26 (1995	5)
	Haynes et al, "Use of Sy	nthetic Peptides	in Primates to Induce High-Titered Ne	utralizing A	239 (1993) atibodies and	MHCC	logo I
	Restricted Cytotoxic T C	cells Against Acc	quired Immunodeficiency Syndrome R	etroviruses.	An HLA-Bas	ed Vacci	ine
	pirategy, Transactions of	of the Association	n of American Physicians 106:33-41 (	1993)			
	Molecular Database, pag	HLA Frequencie	es in Population Cohorts for Design of	HLA-Based	HIV Vaccine	s", HIV	
	Mayr et al, "The Smallpo	ox Vaccination S	train MVA: Marker, Genetic Structure	e. Experience	Gained with	the Pare	ental
	vaccination and Benavio	or in Organisms	with a Debilitated Defence Mechanism	ı", Zbl. Bakt.	Hyg. I. Abt.	Orig. B	ııtaı
	167:375-390 (1978) Bartlett et al. "Safety and	Limmunogenicit	y of an HLA-based HIV envelope poly	unalant annih	-4: 4:1		
<u> </u>	AIDS 12:1291-1300 (19)	98)					
	Haynes et al, "HIV Type	1 V3 Region Pr	imer-Induced Antibody Suppression Is	Overcome b	y Administra	tion of C	C4-V3-
	Peptides as a Polyvalent	Immunogen", A	IDS Research and Human Retroviruse	s 11(2):211-2	21 (1995)		
<del></del>	<del></del>			<del></del>			

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Date Considered

## **INFORMATION DISCLOSURE**

**CITATION** (Use several sheets if necessary) Atty. Docket No.

Divisional of Serial No.

1579-880

09/775,805

**Applicant** 

HAYNES tal

Group

January 9, 2004

			U.S. PATENT DOCUMENTS				
XAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	CLIDOL ACC	FILING	DATE
INITIAL	5,081,226	DATE 1/1992	Berzofsky et al	CLASS	SUBCLASS	IF APPR	OPRIA
	5,019,387	5/1991	Haynes et al		<del> </del>		
	5,013,548	5/1991	Haynes et al				_
	5,352,576	10/1994	Haynes et al				
	5,993,819	11/1999	Haynes et al		<u> </u>		
							-
		FO	REIGN PATENT DOCUMENTS				
						TRANS	LATIO
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	WO 95/29700	11/1995	WIPO				
	WO 97/14436	4/1997	WIPO				
	WO 93/15750	8/1993	WIPO				
	WO 02/024149	3/2002	WIPO	_			
	OTHER DOCL	MENTS (in	cluding Author, Title, Date, Pertinent	pages, et	tc.)		
	_lndividuals", The Journa	ıl of Immuno	c T Lymphocytes Specific for Synthetic Pe ology, Vol. 146, No. 7, pp. 2214-2219 (1991)	)		•	
	HIV Synthetic Peptides'	', Proc. Natl.	nan Immunodeficiency Virus (HIV) CD8 <sup>+</sup> C Acad. Sci. USA, Vol. 88, pp. 9448-9452 (1	991)			
	Haynes, et al., "Convers	ion of an Im	munogenic Human Immunodeficiency Viru	s (HIV) Env	velope Synth	etic Pept	ide to
	Medicine, Vol. 177, pp.	es by the Fu 717-727 (19	sogenic Domain of HIV gp41 Envelope Pro 93)	otein", The	Journal of Ex	perimen	tal
	Haynes, et al., "Induction	n of HIVMN	Neutralizing Antibodies in Primates Using	a Prime-Bo	ost Regimen	of Hybr	id
	Synthetic gp120 Envelop	e Peptides"	The Journal of Immunology, Vol. 151, No.	. 3, pp. 1640	<u>6-1653 (1993</u>	)	
	Glycoprotein of HIV 1 is	ig With I He	lper Cell Epitope Peptides Enhances the An	tibody Resp	onse to the I	Envelope	:
	Liao, et al., "Increased In	nmunogenic	The Journal of Immunology, Vol. 146, No. ity of HIV Envelope Subunit Complexed w	ith $\alpha_2$ -Macr	-1673 (1991) oglobulin W	hen Com	bined
	With Monophosphoryl L	ipid A and C	M-CSF", Vaccine, Vol. 20, pp. 2396-2403	(2002)			
	Histocompatibility Mole	cules", The	Cytotoxic T Cell Epitopes from the HIV-1 Flournal of Immunology, Vol. 148, No. 6, pp	Envelope Pr . 1657-166	otein with M 7 (1992)	ultiple C	lass I

copy of this form with next communication to application.

## **INFORMATION DISCLOSURE CITATION**

Divisional of Serial No.

1579-880 Applicant

Atty. Docket N .

09/775,805

(Use several sheets if necessary)

HAYNES tal Filing Dat

Group

		January	9, 2004					
		U.S.	. PATENT	DOCUMENTS				
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING IF APPR	DATE OPRIATE
				· · · · · · · · · · · · · · · · · · ·				
						<del> </del> -	<u> </u>	
							<u> </u>	
					<del></del>			
				· · · · · · · · · · · · · · · · · · ·			<u> </u>	
					<del>-  </del>		<del></del>	
			<u> </u>					
		-	<del></del>					
	-				<del></del>			
			·					
	<u> </u>	FORFIG	N PATENT	DOCUMENTS		L		
		TOTILIG	HEATEN	DOCUMENTS			TRANS	LATION
	DOCUMENT	DATE		COLINTRY	01.400	011001.400		
	DOGGMENT	DATE		COUNTRY	CLASS	SUBCLASS	YES	NO
								<del> </del>
								<u> </u>
					<del></del>			-
				<del>-</del>				<del></del>
					<del></del>			
	OTHER DOCU	MENTS (include	ding Autho	r Title Date Portino	nt nagas, et	<u></u>		<u> </u>
	Wain-Hobson, "Is Antige	enic Variation of	HIV Import	ant for AIDS and What M	Might Re Evo	ected in the I	Zutumo 2"	The
	Evolutionary Biology of	Viruses. Stephen	S. Morse (e	ed), Raven Press, Ltd., No	ew York, pgs.	185-209 (19	94)	
	Riffkin et al, "A single ai	mino-acid change	e between th	e antigenically different of	extracellular s	serine proteas	ses V2 ar	nd B2
	from Dichelobacter node	osus", Gene 167:2	279-283 (199	95)				
	Abaza et al, "Effects of a	mino acid substit	utions outsi	de an antigenic site on pr	otein binding	to monoclon	al antibo	dies of
	Cruse et al. Illustrated Di	obtained by pep	tide immuni	TRANSLATION  COUNTRY  CLASS SUBCLASS YES NO  TRANSLATION  COUNTRY  CLASS SUBCLASS YES NO  TRANSLATION  TRANSLATION  OF THE PROPERTY OF THE PRO				
	Paul Fundamental Immu	nology (Philadel	nhia & New	Vork Linningst Bayer	s, Inc., p. 309,	QR180.4.C7	78 (1995)	<u>)                                    </u>
	QR181.F84 (1993)	mology (I imade)	pina & New	Tork, Eippincou-Raven	Publishers, p	p. 250, 1311,	, 1312,	
								<del></del>
		-						
Examiner				Date Considered				
	reference considered, whether or			Date Considered			_	

citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

# INFORMATION DISCLOSURE CITATION

Atty. Docket No.

Divisional of Serial No.

1579-880 Applicant 09/775,805

(Use several sheets if necessary)

HAYNES tal

Group

January 9, 2004

						EII INI/	G DATE
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	IF APPR	ROPRIAT
	5,030,449	7/1991	Berzofsky et al				
	5,853,978	12/1998	Berman et al				
	5,864,027	1/1999	Berman				
	5,932,218	8/1999	Berzofsky et al				
	5,939,074	8/1999	Berzofsky et al				
	6,042,836	3/2000	Berman et al				
	6,290,963	_9/2001	Fischinger et al			ļ	
	6,294,322	9/2001	Berzofsky et al				
	6,458,527	10/2002	Luciw et al				
	5,081,226	1/1992	Berzofsky et al				
	5,336,758	8/1994	Berzofsky et al				
	5,622,703	4/1997	Berzofsky et al				
	5,695,762	12/1997	Berzofsky et al				
	5,711,947	1/1998	Berzofsky et al				
	5,820,865	10/1998	Berzofsky et al				
	5,882,853	3/1999	Berzofsky et al				
	5,976,541	11/1999	Berzofsky et al	1			
	5,980,899	11/1999	Berzofsky et al				
	5,997,869	12/1999	Goletz et al				
	6,214,347	4/2001	Berzofsky et al				
	6,592,872	7/2003	Klimpel et al				
		FOF	EIGN PATENT DOCUMENTS				
						ENGLISHA	BSTRAC
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	WO 93/04697	3/1993	WIPO	1	TODOLAGG	123	T
	WO 94/26785	11/1994	WIPO	+	<del>-</del>		
	WO 94/28929	12/1994	WIPO			<u>-</u>	ļ
	WO 94/29339	12/1994					
	<del></del>		WIPO				<u> </u>
	WO 98/01564	1/1998	WIPO				
	WO 02/08716	1/2002	WIPO			X	İ.,
	WO 2002/20554	3/2002	WIPO				_
	OTHER DOCU	MENTS (in	cluding Author, Title, Date, Pertinent	pages, et	ic.)		
	Ahlers, et al., "Construct	ion of an HI	V-1 Peptide Vaccine Containing a Multidet	erminant Ho	elper Peptide	Linked	to a V
	Loop Peptide 18 Inducin	g Strong Ne	utralizing Antibody Responses in Mice of M	Iultiple ME	IC Haplotype	s After	Two
	ummunizations", The Jou	ırnal of Imm	unology, Vol. 150, No. 12, pp. 5647-5665 (	1993)			
1	Ahlers, et al., "Candidate	e HIV Type :	Multideteminant Cluster Peptide-P18MN	Vaccine Co	nstructs Elic	it Type 1	Helpe
İ	I Cells, Cytotoxic T Cel	ls, and Neutr	alizing Antibody, All Using the Same Adju	vant Immui	nization", AI	DS Rese	arch a
	Human Retroviruses, Vo	l. 12, Numbe	er 4, pp. 259-272 (1996)				
	Berzofsky, et al., "Antige	enic Peptides	Recognized by T lymphocytes from AIDS	Viral Enve	lope-Immune	Human	ıs",
	Nature, Vol. 334, pp. 706	5-708 (1988)					

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.